All-Trans Retinoic Acid (atRA) effectively improves liver steatosis in a rabbit model of high fat induced liver steatosis

References

• Amengual, J., et al., 2008. Retinoic acid treatment increases lipid oxidation capacity in skeletal muscle of mice. Obesity, 16 (3), 585–591.
   PubMed Web of Science ®Google Scholar
• Benzie, I.F., and Strain, J.J., 1996. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Analytical biochemistry, 239 (1), 70–76.
   PubMed Web of Science ®Google Scholar
• Bjelakovic, G., et al., 2010. Meta‐analysis: antioxidant supplements for liver diseases–the Cochrane Hepato‐Biliary Group. Alimentary pharmacology & therapeutics, 32 (3), 356–367.
   PubMed Web of Science ®Google Scholar
• Bonet, M.L., Ribot, J., and Palou, A., 2012. Lipid metabolism in mammalian tissues and its control by retinoic acid. Biochimica et Biophysica Acta (BBA) - Molecular and cell biology of lipids, 1821 (1), 177–189.
   PubMed Web of Science ®Google Scholar
• Brun, P.J., et al., 2013. Retinoids: potent regulators of metabolism. BioFactors, 39 (2), 151–163.
   PubMed Web of Science ®Google Scholar
• Byrne, C.D., and Targher, G., 2020. What’s new in NAFLD pathogenesis, biomarkers and treatment? Nature reviews gastroenterology & hepatology, 17 (2), 70–71.
   PubMed Web of Science ®Google Scholar
• Chalasani, N., et al., 2012. The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55 (6), 2005–2023.
   PubMed Web of Science ®Google Scholar
• Chambon, P., 1996. A decade of molecular biology of retinoic acid receptors. The FASEB journal, 10 (9), 940–954.
   PubMed Web of Science ®Google Scholar
• Cioboată, R., et al., 2017. Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. Experimental and therapeutic medicine, 13 (5), 2375–2381.
   PubMed Web of Science ®Google Scholar
• Harrison, S.A., et al., 2009. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology, 49 (1), 80–86.
   PubMed Web of Science ®Google Scholar
• Haukeland, J.W., et al., 2009. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scandinavian journal of gastroenterology, 44 (7), 853–860.
   PubMed Web of Science ®Google Scholar
• Higuera-de la Tijera, F., and Servín-Caamaño, A.I., 2015. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World journal of hepatology, 7 (10), 1297.
   PubMed Web of Science ®Google Scholar
• Jiang, S.-J., et al., 2008. Retinoic acid prevents Chlamydia pneumoniae-induced foam cell development in a mouse model of atherosclerosis. Microbes and infection, 10 (12–13), 1393–1397.
   PubMed Web of Science ®Google Scholar
• Kim, S.C., et al., 2014. All‐trans‐retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade. Hepatology, 59 (5), 1750–1760.
   PubMed Web of Science ®Google Scholar
• Kwak, M.-S., et al., 2015. Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c. Diabetology & metabolic syndrome, 7 (1), 28.
   PubMedGoogle Scholar
• Molina-Jijón, E., et al., 2011. Curcumin prevents Cr (VI)-induced renal oxidant damage by a mitochondrial pathway. Free radical biology and medicine, 51 (8), 1543–1557.
   PubMed Web of Science ®Google Scholar
• Muto, Y., et al., 1996. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. New England journal of medicine, 334 (24), 1561–1568.
   PubMed Web of Science ®Google Scholar
• Öström, M., et al., 2008. Retinoic acid promotes the generation of pancreatic endocrine progenitor cells and their further differentiation into β-cells. PloS One, 3 (7), e2841.
   PubMed Web of Science ®Google Scholar
• Pan, J., et al., 2014. Molecular mechanisms of retinoid receptors in diabetes-induced cardiac remodeling. Journal of clinical medicine, 3 (2), 566–594.
   PubMedGoogle Scholar
• Pellegrini, C., et al., 2015. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype. Oncotarget, 6 (30), 29914.
   PubMedGoogle Scholar
• Rébé, C., et al., 2009. Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor α pathway increases the clearance of apoptotic cells by human Macrophages. Circulation research, 105 (4), 393–401.
   PubMed Web of Science ®Google Scholar
• Sanyal, A.J., et al., 2010. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England journal of medicine, 362 (18), 1675–1685.
   PubMed Web of Science ®Google Scholar
• Trasino, S.E., Benoit, Y.D., and Gudas, L.J., 2015. Vitamin A deficiency causes hyperglycemia and loss of pancreatic β-cell mass. Journal of biological chemistry, 290 (3), 1456–1473.
   PubMed Web of Science ®Google Scholar
• Vernon, G., Baranova, A., and Younossi, Z., 2011. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults. Alimentary pharmacology & therapeutics, 34 (3), 274–285.
   PubMed Web of Science ®Google Scholar
• Yanagitani, A., et al., 2004. Retinoic acid receptor α dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology, 40 (2), 366–375.
   PubMed Web of Science ®Google Scholar
• Zhou, B., et al., 2012. All-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation. Journal of biomedicine and biotechnology, 2012, 1–9.
   PubMedGoogle Scholar
• Zhu, J.-Z., et al., 2016. Clinical guidelines of non-alcoholic fatty liver disease: A systematic review. World journal of gastroenterology, 22 (36), 8226.
   PubMed Web of Science ®Google Scholar